Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 20,607 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Terminated Phase 1 Interventional

FT538 in Subjects With Advanced Hematologic Malignancies

NCT04614636
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
Interventions
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Elotuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Minneapolis, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

NCT03685344
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions
Loncastuximab Tesirine and Durvalumab
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Contributing Factors in the Pathobiology of Airway Remodeling in Obesity

NCT03115632
View directory record Official record
Conditions
Asthma, Obesity, Obesity, Morbid, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational

Multi-center Database Registry to Study Thalamus Changes Using AI in MS

NCT03920995
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

NCT00886795
View directory record Official record
Conditions
Urticaria
Interventions
abatacept (Orencia ®)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT07336472
View directory record Official record
Conditions
Multiple Myeloma
Interventions
IBI3003
Drug
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

NCT00841477
View directory record Official record
Conditions
Hepatitis B Infection, Hepatitis C Infection, HIV Infection
Interventions
hepatitis B vaccine 3 dose schedule (0,1,2 month), HBV Vaccination Self-Efficacy Intervention
Biological · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

NCT00461812
View directory record Official record
Conditions
Asthma
Interventions
Mometasone, Advair
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

NCT00049465
View directory record Official record
Conditions
Cancer
Interventions
fatigue assessment and management, management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional Results available

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467
View directory record Official record
Conditions
Distress, Depression, Grief
Interventions
Psilocybin, Modified brief Supportive Expressive Group Therapy
Drug · Behavioral
Lead sponsor
Joshua Woolley
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

NCT02962492
View directory record Official record
Conditions
Evaluate Ketogenic Stress
Interventions
Exenatide/Exenatide extended release, Dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

NCT03096392
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 21, 2026, 10:23 PM EDT
Not listed No phase listed Observational

Magnetic Resonance Imaging of Intracranial Vasculopathies

NCT03032809
View directory record Official record
Conditions
CNS Vasculitis
Interventions
Vessel Wall MR imaging
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

NCT00415064
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Perifosine, Lenalidomide, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

NCT04948099
View directory record Official record
Conditions
Dendritic Cell -Mediated Rheumatic Diseases
Interventions
VIB1116, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Anniston, Alabama • Clearwater, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

NCT02741999
View directory record Official record
Conditions
Plasma Cell Dyscrasia, Monoclonal Gammopathy
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 2Phase 3 Interventional

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

NCT00612898
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine, lamivudine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Safety and Feasibility Testing of a Smaller Network Version of AIDANET

NCT06633965
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

NCT04124965
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Methadone Effects on Zidovudine (ZDV, AZT) Disposition

NCT00000800
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Active, not recruiting Not applicable Interventional

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

NCT04922736
View directory record Official record
Conditions
Scleroderma, Systemic, Morphea, Graft Vs Host Disease
Interventions
UVA-1 Phototherapy
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

NCT00289211
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
37
States / cities
Hoover, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector

NCT01129544
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Gene transfer
Biological
Lead sponsor
David Williams
Other
Eligibility
Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 10:23 PM EDT